Background. The Department of Veterans Affairs implemented an active surveillance program for methicillin-resistant Staphylococcus aureus (MRSA) in 2007 in which acute care inpatients are tested for MRSA carriage on admission, unit-to-unit transfer, and discharge. Using these data, we followed patients longitudinally to estimate the difference in infection rates for those who were not colonized, those who were colonized on admission (importers), and those who acquired MRSA during their stay. We examined MRSA infections that occurred prior to discharge and at 30, 90, 180, and 365 days after discharge.
nasal swab obtained after verbal informed consent to determine if the patient was colonized with MRSA [8] . During the analysis period, nationwide mean compliance with facility admission, unit-to-unit transfer, and discharge swabbing was 95.3%, 94.6%, and 90.8% [9] . The policy also dictated that patients found to be colonized or infected with MRSA were to be placed in contact precautions [10] . The results of nasal screening were kept in the VA Office of Information and Technology Corporate Data Warehouse.
Study Design and Patient Selection
We conducted a retrospective study using a cohort of inpatient admissions to VA acute care hospitals from January 2008 through December 2015. Our analysis included only those patients who had surveillance testing performed to accurately classify patient colonization status on admission. Patients could have been hospitalized multiple times during our analysis period; however, we restricted our analysis to the first hospitalization for each patient over the 8-year period to simplify interpretation of each identified infection. In analyses with postdischarge MRSA infections as the outcome, we excluded patients who had predischarge MRSA infections so as to capture only incident infections.
We categorized patients as not colonized, importers, or acquirers based on the presence of positive MRSA surveillance tests during their inpatient stay. A patient whose admission MRSA screen and all subsequent screens were negative was classified as not colonized. An importer was one who had a positive MRSA screen upon admission to a facility. An acquirer was defined as a patient who was negative for MRSA on facility admission screening but had a subsequent positive MRSA screen upon unit-to-unit transfer or discharge. During the predischarge period, patients could switch from being not colonized to being an acquirer at the time of their acquisition.
We calculated the proportion of MRSA infections that occurred prior to discharge and at 30, 90, 180 , and 365 days after discharge for each of the 3 colonization groups.
We identified positive MRSA cultures from the electronic microbiology data and used 3 definitions to classify these positive cultures as infections. In the most rigorous definition, the culture was deemed an infection if it was taken from a previously sterile body site (eg, blood, bone, or a device). More than 88% of these were from blood. Next, we expanded this definition to include cultures taken from nonsterile sites that were accompanied by prescription of a MRSA-specific antibiotic (ie, parenteral vancomycin, daptomycin, linezolid, clindamycin, doxycycline, or trimethoprim-sulfamethoxazole) within 5 days of the culture date [11] . Finally, we further expanded our MRSA infection definition to include all positive MRSA nonsurveillance clinical cultures. We stratified these calculations by whether the patient was admitted directly to the intensive care unit (ICU).
Statistical Analysis
We performed multivariable regression analysis to examine the association between colonization status and pre-and postdischarge infections. A Cox proportional hazards model with time-varying covariates was used for the predischarge infection outcome. In this analysis, patients who acquired MRSA colonization contributed person-time to the not colonized group prior to acquisition. For postdischarge infection outcomes, we used logistic regression. The regression models controlled for patient demographics (age, sex, marital status, insurance status), the Charlson/Elixhauser hybrid comorbidity index [12] , direct admission to the ICU, colonization pressure (defined as the rate of positive MRSA surveillance tests and rate of MRSA infections per patient day per quarter at the facility level), surgery during the first 48 hours of hospitalization, calendar year, and a hospital fixed effect which controlled for variation in MRSA admission prevalence, bed size, and complexity level across facilities [13] . In secondary analyses, we also stratified these models by whether the patient was admitted directly to the ICU. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, North Carolina) and Stata 15.1 (StataCorp, LLC, College Station, Texas) software.
This study was approved by the University of Utah Institutional Review Board and the Salt Lake City VA's Office of Research and Development.
RESULTS
There were 985 626 (903 348 with no direct ICU admission and 82 278 with direct ICU admission) first admissions to VA acute care hospitals nationwide from January 2008 through December 2015 who had surveillance tests performed for MRSA carriage. Fully 983 916 of these who did not have a MRSA infection during hospitalization were followed for infection after discharge. Approximately 94% were male with a mean age of 64.8 years and 71% were white. Overall, 903 190 (91.6%) patients were found to be not colonized with MRSA during their hospitalization, 72 388 (7.3%) were importers, and 10 048 (1.0%) acquired the organism after admission ( Table 1 ). The median time to acquisition was 14 (interquartile range, 6-33) days. The mean (median) duration of hospitalization for those who did not have predischarge MRSA infections was 4.5 (3), 6.0 (3), and 18 (8) days for those who were not colonized, importers, and acquirers, respectively.
Before hospital discharge, there were 200 sterile site MRSA infections that appeared in the patients in our cohort who were not admitted to the ICU and 163 in those who were admitted to the ICU during the 8-year analysis period ( (Table 1 ). In the latter category, MRSA infection rates ranged from 1.26% to 2.74% for non-ICU importers and acquirers, respectively, and 6.71% to 7.07% for ICU importers and acquirers, respectively. Across all MRSA infection definitions and venues, the unadjusted relative risk for infection was 11.7-60.3 for colonized patients relative to noncolonized patients. Table 2 shows the unadjusted MRSA infection rates for patients without an ICU stay 30, 90, 180, and 365 days after hospital discharge. As in the case of predischarge infections, patients who were colonized had the highest risk of infection and the percentage of those who progressed to infection was similar between those who imported and those who acquired colonization during hospitalization. For instance, during the 180-day postdischarge period, 4.26% of importers had MRSA infections defined as any positive nonsurveillance culture whereas 4.32% of acquirers had MRSA infections using this definition. Compared to those without colonization, the relative risk of MRSA infection was 8.4 for importers and 8.5 for acquirers in this time window. Similar results were found for MRSA infections in the postdischarge period for ICU patients (Table 3) . For these patients, 4.94% of importers and 5.11% of acquirers had MRSA infections identified in the 180-day postdischarge period. The relative risk of infection during this time period was 6.3 for importers and 6.5 for acquirers relative to patients who were not colonized.
The proportion of MRSA infections that occurred after discharge was dependent upon the colonization category and the interval evaluated since discharge ( Figure 1 ). When measured at 180 days postdischarge, 63.9% of pre-and postdischarge infections among importers occurred during the postdischarge period. For acquirers, this value was 61.2%.
In a multivariable regression analysis accounting for patient demographics and other confounders, the hazard ratio for a predischarge MRSA infection defined as a positive nonsurveillance culture was 29.6 (95% confidence interval [CI], 26.5-32.9) for importers and 28.8 (95% CI, 23.5-35.3) for acquirers compared to those not colonized (Table 4) . During the 180-day postdischarge period, the odds ratios for infection relative to those not colonized were 7.7 (95% CI, 7.3-8.1) for importers and 7.5 (95% CI, 6.8-8.3) for acquirers. Finally, results were similar after stratifying on direct ICU admission (Supplementary Tables 1 and 2 ).
DISCUSSION
Being colonized with MRSA increases the risk of subsequent infection during and after hospitalization. For Veterans in our cohort who were not admitted directly to the ICU, 5.5% of patients who imported MRSA and 7.0% of those who acquired MRSA during their inpatient stay had an infection-defined as a positive nonsurveillance culture-either in the predischarge or 180-day postdischarge period. For those with a direct admission to the ICU, 11.4% of importers and 11.7% of acquirers had an infection during the predischarge or 180-day postdischarge period. Both importers and acquirers had a >20-fold increased risk of infection compared to those who were not colonized in the predischarge period, although there was no difference in risk between acquirers and importers. This relative increase in infection risk remained elevated over the 1-year period following discharge. Others studies have reported MRSA infection rates among colonized patients that are up to 11-fold higher than what we found in our analysis [14] [15] [16] [17] . However, comparison with our results is difficult because of differences in colonization definitions, venues, and length of follow-up. For instance, several studies were limited to single units in acute care (ICU, transplant), long-term care, or outbreaks, or were performed before the advent of efficacious bundles to prevent central line bloodstream infections and ventilator-associated pneumonias [18, 19] .
Perhaps more importantly, differences in infection rates may be due to our use of universal surveillance to identify colonized patients compared to others who may have relied primarily on clinical cultures [14] [15] [16] . We and others have shown that universal surveillance identifies approximately 10 times as many colonized patients compared to clinical cultures alone [8, 20] . Of note, our estimate of MRSA infection rates among colonized patients is more in line with those who used universal surveillance. Robicsek et al, for instance, found that 7.4% of patients colonized on admission developed a MRSA infection [21] , Balm et al found that 14.4% developed a MRSA infection [22] , and Ramarathnam et al reported that 8.5% of colonized patients progressed to a MRSA infection [23] .
We did not find a significant difference in MRSA infection risk between importers and acquirers. Although others have reported a difference, studies that have examined this were small (<80 patients) and only followed patients until discharge. In one study, the risk of MRSA bacteremia was 11-fold higher for importers and 29-fold higher for acquirers compared to those who remained noncolonized [24] . In another study, 19% of importers and 25% of acquirers developed a MRSA infection [25] .
Our unique data also allowed us to identify MRSA infections that occurred following hospital discharge. Our results show that a sizable portion of likely hospital-acquired MRSA infections presented after discharge, and, not surprisingly, this portion increases as the follow-up interval increases. For both importers and acquirers, nearly two-thirds of the total MRSA infections in both the predischarge and 180-day postdischarge time periods occurred during the postdischarge period.
The optimal time for follow-up that provides the best likelihood that an infecting organism is a clone of that acquired during hospitalization is not precisely known. Several recent studies have linked colonizing and infecting organisms across wide ranges of time between the colonization and infection events. It has been shown, for instance, that colonizing S. aureus strains may be concordant with those causing bacteremia up to 14 months later, indicating that even our 365-day time period may been too short to capture some infections associated with an acquisition event [26] . Others have shown that ≥85% of MRSA strains isolated from a colonized site and the bloodstream up to 6 months later may be clonal [27] . Especially relevant to our results is work showing that >86% of colonizing MRSA strains recovered from 77 Veterans were concordant with those recovered from infection in the same patients a mean of 251 days later [28] .
The results of our analyses are consistent with previous studies showing that MRSA colonization during hospitalization places patients at an increased risk for postdischarge infection. In a matched-cohort study of patients admitted to a VA hospital and followed for 2 years, there were no culture-proven MRSA infections on readmission among noncarriers, but 13.8% of MRSA carriers had infections [29] . Others have shown that inclusion of 30-day postdischarge data tripled the incidence of acute care hospital-onset MRSA infections, with the median onset being 12 days after discharge [30] . In a recent analysis from the Centers for Disease Control and Prevention, nearly two-thirds of previously hospitalized patients who subsequently developed invasive MRSA developed their infection within 3 months of hospital discharge, consistent with a higher risk of invasive MRSA in the weeks following hospitalization [1] . These data are consistent with the median time from MRSA detection to invasive disease reported by others (15.5-56 days) [15, 21] being longer than the average length of stay in non-VA US hospitals (4.5 days) [31] . Our results are important in the context of the recent debate over the appropriate role of contact precautions for MRSA, highlighted by several high-profile opinion pieces [32, 33] . Several studies showing no change in MRSA HAIs when contact precautions were discontinued for colonized or infected patients relied on monitoring incident infections during an inpatient stay in a mixed importer/acquirer cohort [3] [4] [5] [6] 34] . Our data suggest that contact precautions would likely have a small effect on predischarge HAIs but a larger effect on postdischarge HAIs. For these reasons, the value of contact precautions for MRSA should be judged in the context of infections that occur only in acquirers (excluding importers since acquisition is what contact precautions are designed to prevent) and should include infections that occur after discharge.
Our study has several limitations. First, patients may have sought care outside the VA system following discharge. Because we were only able to identify postdischarge patient outcomes through encounters at VA facilities, we have not accounted for postdischarge infections that were identified in non-VA settings. Second, the standardized protocols at VA hospitals during this time indicated that surveillance specimens were to be taken from the nares. However, patients can carry MRSA in other locations on their body. Therefore, some patients who were colonized with MRSA may have been misclassified as not colonized in our data. Third, because of the difficulty in identifying true infections from electronic microbiology data, we used several definitions of MRSA infection. It is possible that some of these positive cultures were not true infections and that we missed some infections whose isolates were taken from nonsterile sites and not treated. The challenges of identifying infections in the electronic data extend to the timing of infection as well. In our experience, while the VA microbiology data accurately capture the timing of culture collection or processing by the laboratory, there may be a small number of instances in which this does not accurately represent the timing of infection. For example, a culture may be delayed because a clinician initially feels that empiric treatment without culture is sufficient or because of a surgical procedure. Finally, isolates were not collected from surveillance and subsequent infection and compared to confirm clonality, although others have shown that MRSA infection in Veterans following initial colonization is caused by the same strain in many cases [28] .
In conclusion, acquisition of MRSA during hospitalization markedly increases the risk to a patient of subsequent infection that may not become manifest until after discharge. These factors should be taken into account when optimizing infection control strategies for MRSA.
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